Clinical Trials
36 trialsNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
M.D. Anderson Cancer Center
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ECHOS
Santa Chiara Hospital
GemTax
University of Pittsburgh
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
Dana-Farber Cancer Institute
MATEO
AIO-Studien-gGmbH
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
University of Wisconsin, Madison
AINO
Tampere University Hospital
MICADO
International Group of Endovascular Oncology
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Ohio State University Comprehensive Cancer Center
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Molecularly Tailored Therapy for Pancreas Cancer
Georgetown University
Docetaxel and Lycopene in Metastatic Prostate Cancer
Medical University of South Carolina
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
The University of Texas Health Science Center, Houston
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase II Study for Solid Metastatic Tumors
NYU Langone Health
Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer
Zhejiang Cancer Hospital
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
University of Southern California
Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone
University of Washington
A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer
Japan Clinical Oncology Group
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
Centro Nacional de Investigaciones Oncologicas CARLOS III
MYOTAX
Catharina Ziekenhuis Eindhoven
MYOHERTAX
Catharina Ziekenhuis Eindhoven
Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC
University of Kentucky
Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer
Fudan University
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
M.D. Anderson Cancer Center
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
Providence Health & Services
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Docetaxel and Capecitabine in Advanced Gastric Cancer
Charite University, Berlin, Germany